Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 10/26 10:00:29 pm
114.56 USD   +0.53%
10/26 JOHNSON & JOHNS : to Participate in the 25th Annual Credit Suisse He..
10/26 JOHNSON & JOHNS : Research Reports on Drug Makers Equities -- Pfizer..
10/24 JOHNSON & JOHNS : Hepatitis B Virus Market (HBV) Review with 2016-20..
News SummaryMost relevantAll newsSector news 

J&J's Simponi Helps Colitis Patients In Clinical Trial

share with twitter share with LinkedIn share with facebook
share via e-mail
05/21/2012 | 08:45pm CEST
   By Peter Loftus 

Johnson & Johnson (>> Johnson & Johnson) said its drug Simponi improved symptoms in a majority of patients with an inflammatory-bowel disease in a new clinical trial.

The results, released at a medical conference Monday, could support expansion of the approved uses of Simponi to include treating the bowel condition, known as ulcerative colitis, which J&J estimates affects about 700,000 people in the U.S.

Simponi, which was introduced in 2009, is currently approved to treat signs and symptoms of moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.

Simponi is known as an anti-tumor necrosis factor, or anti-TNF, a category that also includes J&J's older drug, Remicade, which is already approved to treat ulcerative colitis. Simponi can be self-administered by patients as an injection, while Remicade requires intravenous infusion by a health-care provider.

J&J recorded $410 million in Simponi sales for 2011; Merck & Co. (MRK), which markets the drug in certain countries outside the U.S., recorded $264 million in Simponi sales for 2011.

J&J tested Simponi in a late-stage clinical trial of more than 770 patients with moderately to severely active ulcerative colitis who had failed to respond to or tolerate certain other treatments.

Some patients received Simponi--at two different dose levels--and some received a placebo, and researchers tracked how many experienced a clinical response at six weeks after the start of treatment. Clinical response included improvements in various symptoms of ulcerative colitis such as diarrhea.

According to J&J, 51.8% and 55% of patients in the two Simponi groups, respectively, achieved a clinical response at week 6, versus 29.7% of placebo patients. The results were presented Monday at the Digestive Disease Week medical meeting in San Diego.

In a secondary measure in the trial, roughly 18.7% and 17.8% of patients in the Simponi groups had clinical remission, versus 6.3% in placebo patients.

The rates of adverse events were comparable among the Simponi and placebo groups, and J&J said the safety of Simponi in the colitis study was consistent with the drug's safety profile in the diseases for which it's already approved.

As a class of drugs, Simponi and other anti-TNFs are associated with increased risk of infections and certain forms of cancer such as lymphoma.

The data suggest Simponi could be a new treatment option for ulcerative colitis patients who don't respond to other drugs, or who prefer the convenience of a subcutaneous injection, said William Sandborn, chief of the division of gastroenterology at the University of California, San Diego, and lead investigator of the J&J-funded study.

J&J also has studied Simponi over a longer treatment duration in colitis patients, and results are expected later this year.

J&J plans to apply for U.S. and European regulatory approval of Simponi as a treatment for ulcerative colitis this year, said J&J spokesman Brian Kenney.

Abbott Laboratories (>> Abbott Laboratories) also has applied for regulatory approval of its anti-inflammatory drug, Humira, as a treatment for ulcerative colitis. European regulators have approved the new indication.

Last year, the FDA declined to approve J&J's requests to market Simponi's ability to inhibit progression of structural damage in both rheumatoid arthritis and psoriatic arthritis.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Johnson & Johnson, Abbott Laboratories
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
10/26 JOHNSON & JOHNSON : to Participate in the 25th Annual Credit Suisse Health Care ..
10/26 JOHNSON & JOHNSON : Research Reports on Drug Makers Equities -- Pfizer, Merck, A..
10/24 JOHNSON & JOHNSON : Hepatitis B Virus Market (HBV) Review with 2016-2025 Forecas..
10/24 JOHNSON & JOHNSON : Davenport Co buys $162,560,871 stake in Johnson & Johnson
10/24 JOHNSON & JOHNSON : As achievement gap widens, Phoenixville schools seek ways to..
10/22 JOHNSON & JOHNSON : to buy wind power in the US
10/22 JOHNSON & JOHNSON : Carlton Hofferkamp Jenks Wealth Management buys $2,342,903 s..
10/21 JOHNSON & JOHNSON : U.s. fda approves vermox chewable (mebendazole) for treatmen..
10/21 JOHNSON & JOHNSON : E.ON inks 100MW wind power deal with Johnson & Johnson
10/20 JOHNSON & JOHNSON : Announces Quarterly Dividend for Fourth Quarter 2016
More news
Sector news : Pharmaceuticals - NEC
10/26 GLAXOSMITHKLINE : British imports of cheap medicines dry up as pound falls
10/26DJGlaxo Profit Jumps on Weaker Pound
10/26 Bayer third-quarter profit beats forecasts on pharma, pesticides
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/26 INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Cree, mcc, reed, erc
10/26 GLOBAL BLOOD THERAPEUTICS : Incredible Value At This Price
10/26 Create Your Own Johnson & Johnson Dividend
10/26 After Positive P2B Results, Tiny, De-Risked Genocea Is Severely Undervalued
10/26 Where I Went Wrong On Gilead
Financials ($)
Sales 2016 72 080 M
EBIT 2016 21 940 M
Net income 2016 16 371 M
Finance 2016 19 430 M
Yield 2016 2,74%
P/E ratio 2016 19,38
P/E ratio 2017 17,09
EV / Sales 2016 4,08x
EV / Sales 2017 3,80x
Capitalization 313 422 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON11.53%313 422
ROCHE HOLDING LTD.-17.44%196 913
PFIZER INC.0.37%196 527
NOVARTIS AG-16.42%188 199
MERCK & CO., INC.15.24%168 318
More Results